Drug Profile
Ondansetron/pyridostigmine - DAS Therapeutics
Alternative Names: DAS-001; GTB-004; GTP-004Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Georgetown Translational Pharmaceuticals
- Developer GT Biopharma
- Class Antiemetics; Carbamates; Carbazoles; Imidazoles; Pyridines; Quaternary ammonium compounds; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Myasthenia gravis
Most Recent Events
- 08 Apr 2021 Phase-II clinical trials in Myasthenia gravis in USA (PO) (NCT04226170)
- 28 Jan 2021 No recent reports of development identified for phase-I development in Myasthenia-gravis in USA (PO, Tablet)
- 23 Jan 2020 Chemical structure information added